M&A / Deals Cardio biotech Kardigan binds off $400M upsized IPO BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.CardiovascularRead full story pharminent June 18, 2026 (Last updated: June 19, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: GSK claims FDA okay for first oral carbapenem antibioticNext: Heart drug biotech Kardigan raises $400m in upscaled IPO Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
